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Abstract. The uptake of E -combretastatins, potential prodrugs of the anticancer Z -isomers, into multicellular
spheroids has been imaged by intrinsic fluorescence in three dimensions using two-photon excited fluorescence
lifetime imaging with 625-nm ultrafast femtosecond laser pulses. Uptake is initially observed at the spheroid
periphery but extends to the spheroid core within 30 min. Using agarose gels as a three-dimensional
model, the conversion of Z ðtransÞ → EðcisÞ via two-photon photoisomerization is demonstrated and the location
of this photochemical process may be precisely selected within the micron scale in all three dimensions at depths
up to almost 2 mm. We discuss these results for enhanced tissue penetration at longer near-infrared wave-
lengths for cancer therapy and up to three-photon excitation and imaging using 930-nm laser pulses with suitable
combretastatin analogs. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or repro-
duction of this work in whole or in part requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.JBO.20.7.078003]
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1 Introduction
Multiphoton absorption, first proposed in 1931 by Göppert-
Meyer and demonstrated with lasers in the 1960s,1,2 is now
widely employed in multiphoton-excited fluorescence micros-
copy.3,4 Two- or three-photon excitations (2PE or 3PE),
which have very low absorption cross sections, most readily
occur at the high photon density within the femtoliter focal vol-
ume of a subpicosecond pulsed-laser excitation beam which
may then be scanned across a sample to construct a fluorescence
image. An important advantage in both biological imaging and
phototherapy is that multiphoton excitation shifts the required
wavelength to the red or near-infrared (NIR) spectral regions
where light transmission in human and animal tissues is
much greater than at shorter wavelengths.5 However, a major
concern relates to the depths that may be probed within a sample
which is dependent upon several factors: light penetration and
good transmission with low scattering combining to permit the
necessary high peak laser power at the focus.6,7 For three-dimen-
sional (3-D) imaging of intact tissues, the choice of wavelength
is important and recent work suggests that wavelengths even
longer than the commonly used wavelengths ranging from
∼700 to 1000 nm may be optimal.8 For fixed tissues, optical
clearing methods have been devised that substantially increase
the sample transparency.9 The issue of multiphoton excitation
has also been addressed by microscope manufacturers now
offering specially designed objective lenses to optimize deep
light penetration in tissues which combine specifications such
as long working distance, silicon oil immersion for precise
refractive index matching, chromatic aberration minimization,
and high numerical aperture.
In addition to imaging studies, two-photon excitation is of
increasing interest in the field of photodynamic therapy
(PDT). Conventional PDT depends on photoexcitation of a
drug capable of forming a triplet state, which may then either
react directly with a biomolecule to form a radical species
(Type I mechanism) or transfer energy to triplet ground-state
dioxygen to form reactive excited singlet oxygen (Type II
mechanism).10–12 Type I photosensitization may involve gener-
ation of reactive oxygen species (superoxide and hydrogen per-
oxide) or lipid and protein radicals. In the latter instance, as with
some phenothiazinium derivatives, photosensitization may be
independent of oxygen.13,14 This is highly desirable in practice
since for photosensitization to be effective, for example, in
instances where the vasculature is disrupted as in hypoxic
tumor regions, Type II and some oxygen-dependent Type I
mechanisms are inoperative. Two-photon excitation allows
the activation wavelength to be shifted into the NIR region,
improving the specificity of excitation of PDT photosensitizers
while avoiding absorption by natural chromophores in the tis-
sue, and increasing the tissue depth at which PDT may be deliv-
ered to a tumor.15–17 Two-photon PDT may be achieved by using
a sufficiently intense optical field (up to 800 mW) within a
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defined region, with maximum effective depths estimated
between 2 and 4 cm in tumor models and collagen gel phantoms,
respectively.17 It is our purpose to explore well-focussed laser
beams at very much lower power levels.
Combretastatins are derivatives of natural products from the
African bush willow tree, Combretum caffrum. They are all 1,2-
diarylethenes that, as the Z-isomers bind strongly to tubulin, dis-
rupt polymerization and microtubule function.18–20 This results
in direct toxicity to tumor cells and in the destruction of tumor
vasculature through inhibition of angiogenesis. Z-combretasta-
tins such as combretastatin A4 (CA4, Fig. 1) have been inves-
tigated as anticancer agents in clinical trials, and have largely
proven to be effective in combination with other drugs such
as carboplatin, although toxic side effects appear to be limiting
their usage.21,22 We have proposed that systemic toxicity of
the Z-ðcis-Þisomer might be avoided by photoisomerization
of the less toxic E-ðtrans-Þisomer by targeted photoirradiation
at a tumor site (Fig. 1).23–25 While Z-combretastatins are non-
fluorescent, the intrinsic fluorescence of E-combretastatins
has enabled real-time monitoring of E-combretastatin uptake
in monolayers of live mammalian cells by two-photon excitation
fluorescence lifetime imaging (2PE-FLIM).23,24 E-combretasta-
tins have fluorescence lifetimes that are dependent on solvent
polarity and viscosity and were shown to be proportional to
fluorescence quantum yields. Through measurement of both
fluorescence intensity and lifetimes, it was possible to evaluate
intracellular concentrations. E-Combretastatins were found to
accumulate in the cytoplasm and within intracellular lipidic
structures including lipid droplets at millimolar concentrations.
Once within the cell, the E-combretastatin (absorption
λmax ∼ 320 nm) may be activated by two-photon absorption
at 625–630 nm and the resulting cell death demonstrated
using fluorescence assays.25 Both two-photon irradiation and
fluorescent assays using confocal imaging may be performed
using a single adapted microscope system.26 The present report
moves our previous work with combretastatins in monolayer
cell cultures into 3-D model systems to demonstrate prodrug
uptake and activation at depth within a model tissue structure.
It is widely considered that tumor spheroids consisting of an
assembly of several thousand cells offer more realistic tissue
models27–29 and are, therefore, used here to study the intracel-
lular uptake of fluorescent E-combretastatins in three dimen-
sions over time.
Thick agarose gels are used as a scattering 3-D model to
demonstrate the Z- → E- combretastatin photoisomerization
by two-photon excitation at increasing depth with highly local-
ized specificity. Previously, we established ∼630 nm excitation
to be an effective wavelength to achieve photoisomerization of
combretastatins, but deep tissue penetration of the excitation
light is best achieved using wavelengths even further shifted
toward the NIR (>800 nm). Hence, experiments in solution
were also carried out to investigate the potential of three-photon
isomerization and activation of an E-combretastatin at these
longer wavelengths of between 800 and 1000 nm where
there is less scattering and where interference from melanin
absorption is also reduced.
2 Materials and Methods
2.1 Cell Culture and Maintenance
C8161 human melanoma cells were a gift from Meyskens
(University of California, Irvine) and were established from
abdominal wall metastasis from a menopausal woman with
recurrent malignant melanoma.30 Human metastatic breast
cancer MDA231 cells were obtained from Currell’s group at
the Queen’s Belfast University. C8161 melanoma cells were
routinely cultured in T75 tissue culture flasks using phenol-
red free minimum essential medium (MEM) supplemented
with 10% FBS, 100 units∕mL penicillin, 100 mg∕mL strepto-
mycin and L-glutamine (2 mM). MDA 231 cells were main-
tained in phenol-red free DMEM (high glucose) containing
the same supplements. The cells were stored under a humidified
atmosphere at 37°C with 5% CO2. All cell culture materials
[fetal bovine serum (FBS)], penicillin, streptomycin, L-gluta-
mine, phosphate buffered saline (PBS, 1×), 0.5% trypsin-
EDTA (10×), MEM and Dulbecco’s modified Eagle’s medium
(DMEM) were purchased from Gibco®. Glass-bottom culture
dishes (35 mm diameter, No. 1.5, uncoated, γ-irradiated) were
obtained from MatTek Corporation, USA, and sterile 96-well
round-bottom plates were purchased from BD Falcon. Agarose
powder (99%) for multiwell-plate coating was purchased from
Sigma-Aldrich.
2.2 Growth of Multicellular C8161 and MDA
Spheroids
Multicellular spheroids from C8161 and MDA 231 cells were
grown in round-bottom 96-well plates coated with sterile agar-
ose gel 1.5% in PBS (100 μL∕well). The agarose gel was left to
set for 1.5 h at room temperature in a sterile environment prior to
cell seeding. C8161 or MDA 231 cell suspensions (100 μL),
respectively, with concentrations of 10 × 104 cells∕mL were
added to each well and the wells were topped up with an
extra 100 μL of the corresponding complete media. The 96-
well plates were stored for 3 to 7 days in a humidified incubatorFig. 1 Structures of the compounds used in this work.
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at 37°C with 5% CO2 to allow spheroid formation (normally
visible after 24 to 48 h). No cells were added to the outer
wells of the 96-well plates since they are prone to evaporation
of cell culture media. Instead, they were filled with PBS
(200 μL) to prevent evaporation of culture media from the
edges. After 3 to 7 days, multicellular spheroids with average
diameters of ∼200 to 500 μm were harvested and carefully
transferred from their well onto MatTek glass-bottom culture
dishes and immersed in FITC-dextran (final concentration
0.25 mg/mL, Sigma-Aldrich) containing medium for micro-
scopic examination.
2.3 Confocal and Two-Photon Fluorescence
Lifetime Imaging of Multicellular Spheroids
Confocal and multiphoton fluorescence lifetime imaging of
MDA 231 and C8161 multicellular spheroids was carried out
using an inverted Nikon TE2000-U microscope attached to a
Nikon C2 scanning unit. The imaging was carried out using
a Nikon Plan Apo VC 60× water immersion objective (N.A.
1.2, WD 0.31 to 0.28 mm) or Nikon Plan Apo Lambda 20×
air objective (N.A. 0.75, WD 1 mm). Experiments with a single
spheroid of each cell type were performed in triplicate and pro-
duced similar results. For two-photon excitation and fluores-
cence lifetime imaging microscopy via time-correlated single-
photon counting at ∼625 nm, a laser beam (from a Ti-sapphire
laser producing 180 fs pulses at 76 MHz, pumping a Mira OPO)
was directed through the confocal scan head onto the sample.
The microscope setup has been described in detail elsewhere.26
Fluorescence lifetimes were measured using the time-correlated
single-photon counting method using a R3809U photomultiplier
(Hamamatsu) and a Becker and Hickl SPC 830 module. For
FLIM studies of E-combretastatin fluorescence, a combination
of Comar 400IU25 and BG3 filters were used in front of the
photomultiplier. FLIM data were analyzed using the SPCImage
software package (Becker and Hickl). E-Combretastatin con-
centrations (Cs) in tumor spheroids were calculated from the
fluorescence intensity (Is, counts∕pixel) and lifetime (τs) using
the relationship Cs ¼ ðIs · Cr · τsÞ∕ðIr · τrÞ, where the standard
reference values ðCr; Ir; τrÞ were obtained using solutions of E-
combretastatin in dimethyl sulfoxide. For imaging cells using
two-photon excitation, laser powers were <1 mW and the
laser scanned with a typical dwell time of 1.68 μs and a pixel
size of 1.4 μm. E- and Z-isomers of combretastatin CA4 (CA4),
a fluorinated analog (CA4F), and a 4-cyano analog (4-[2-(3,4,5-
trimethoxyphenyl)vinyl]benzonitrile, CA4CN) were prepared as
previously described14,15 and structures are shown in Fig. 1.
2.4 Isomerization in Agarose Gels
An aliquot (50 μL) of agarose (1% in PBS) containing Z-CA4F,
Z-CA4 or Z-CA4CN (1 mM), respectively, was pipetted into a
μ-Slide Angiogenesis (Ibidi®) microwell. After setting, the gel
was overlaid with PBS (10 μL) to prevent it from drying out
during the experiment. At this concentration, the Z-combretas-
tatins form microcrystals in the gel. Irradiations were performed
using the same inverted microscope system as described above,
but in addition to the two microscope objectives described in the
previous paragraph, irradiations also used a Nikon CF175 Apo
25 ×W MP (NA 1.10 WD 2.0, a kind loan from Nikon United
Kingdom) water dipping objective, specifically designed for
multiphoton applications. X-Y planes of the gel (83 × 112 μm2)
were irradiated with the laser beam (625 nm, 8.4 mW average
power, total time 150 s, pixel dwell time 60 μs) focused at
increasing height (Z-dimension) into the gel. Following the irra-
diations, a Z-stacked image of the gel was acquired using the
625-nm laser beam attenuated to 0.8 mW (500 μm2 XY
field, 75 s accumulation 1.68 μs pixel dwell time) with emission
detected with the blue channel of the confocal accessory.
Maximum projection of the irradiated Z-stack image was ana-
lyzed using ImageJ software.
2.5 Multiphoton Excitation Spectra of E-CA4CN
Multiphoton excited fluorescence spectra were recorded by
exciting a solution of E-CA4CN in dimethylsulfoxide
(DMSO) (10 mM) at wavelengths between 800 to 960 nm
using the output from the femtosecond pulsed Ti-sapphire
laser at laser powers ranging from ∼0.1 to 6 mW at the sample.
The excitation light was delivered to the sample through the
Nikon Plan Apo VC 60× water immersion objective (N.A.
1.2, WD 0.31 to 0.28 mm) without scanning the laser beam.
The spectrograph (Acton 275) for the measurement of two-
and three-photon excited emission spectra was calibrated
using a Hg-lamp. Spectral detection was achieved using an
Andor charge-coupled device camera.
3 Results and Discussion
3.1 Imaging and E-combretastatin Uptake in Cell
Spheroids.
Tumor cell spheroids are widely considered as a closer model to
tissues than cell monolayers since they are 3-D structures and
display some of the characteristics of solid tumors such as low
central oxygen tension and a necrotic central core.27–29 They are
suitable for imaging studies to an extent, but previous studies
noted difficulty in resolving complete spheroid structures due
to low light transmission and high scattering by the spheroid
equator.28,29,31 Figure 2 shows the orthogonal views of a negative
image of a melanoma C8161 cell spheroid suspended in a
FITC-dextrin solution reconstructed from confocal Z-scans,
together with depth-resolved images. The negative image of the
spheroid, with a diameter of ∼250 μm (volume 8.2 × 106 μm3
and estimated to contain ca. 16,000 cells based on a single cell
diameter of 10 μm (volume 520 μm3), shows that an overall
approximately hemispherical shape of the lower half of the
spheroid is clearly resolved in the fluorescent suspending
medium by the inverted microscope by imaging of sections
upward from the cover slip toward the equator (to ∼100 μm).
However, the top half of the spheroid is essentially represented
as a shadow due to absorption and scattering by the lower half of
the spheroid. This is very similar to results of cell spheroid im-
aging previously reported.31 However, despite this issue, our
results show (Fig. 3) that 3-D investigations of drug uptake are
feasible at depths up to 80-100 μm into the structure using two-
photon excited confocal imaging.
E-combretastatins are fluorescent with fluorescence lifetimes
that are dependent on their environment, including local viscos-
ity that affects the isomerization rate.23,24 Uptake and distribu-
tion of E-combretastatin A4 (E-CA4) in cell monolayers of
melanoma C8161 cells has been studied by real-time FLIM.
As in other cells previously studied,23 uptake of E-combretas-
tatin is fast (t1∕2 < 2 min) and the compound is mainly located
at intracellular loci that have been identified as membranes and
lipid droplets.23 The fluorescence lifetime of the intracellular
Journal of Biomedical Optics 078003-3 July 2015 • Vol. 20(7)
Scherer et al.: Three-dimensional imaging and uptake of the anticancer drug combretastatin. . .
Downloaded From: http://biomedicaloptics.spiedigitallibrary.org/ on 08/12/2015 Terms of Use: http://spiedigitallibrary.org/ss/TermsOfUse.aspx
fluorescence has a distribution that peaks at ca. 1000 ps, longer
than in solution (e.g., 280 ps in ethanol and 860 ps in hexane),
resulting from a viscous lipidic environment.
Results from FLIM of E-CA4 uptake in C8161 spheroids are
shown in Fig. 3. The full depth of the spheroid cannot be imaged
as noted above, and the observed images of E-combretastatin
fluorescence after uptake over a range of imaging depth
[Figs. 3(b1) to 3(b7)] show an approximate 60% decline in
intensity at 75 μm compared with 25 μm [Fig. 3(d)]. To observe
the kinetics of uptake, an optical section at 75 μm into the
spheroid (i.e., above the cover slip) was selected and imaged
using the pseudoconfocal nature of two-photon excitation.
Images at selected time intervals after addition of E-CA4
(25 μM) to the medium are shown in Figs. 3(a1) to 3(a12), and
reveal initial rapid uptake into the peripheral cells in this section
at a rate similar to that in monolayers. After about 10-min incu-
bation, there is significant movement of E-CA4 into the
center of the spheroid image plane. Finally, in the last image,
Fig. 3(a12), the drug appears relatively evenly distributed within
this spheroid section. Similar results were obtained for E-CA4F
Fig. 2 Orthogonal views (a) of a melanoma C8161 cell spheroid suspended in a solution of FITC-dextran
(0.25 mg∕ml, MW ¼ 40;000 Da), producing a negative image of the spheroid (all views at the same
scale). The views are reconstructed from a Z-stack of confocal images with excitation of FITC-dextran
at 488 nm. Images (b) to (i) show defined planes of spheroid at the indicated distances from the coverslip.
Fig. 3 Uptake of E -CA4 into a C8161 melanoma cell spheroid at 20°C measured using fluorescence
lifetime microscopy (FLIM) with two-photon excitation at 625 nm. (a1)–(a12) A plane 75 μm up from the
base of the spheroid using intrinsic E -CA4 fluorescence at the indicated times after addition of E -CA4
(25 μM) to the suspending medium. (b1)–(b7) Planes at the indicated depths within the spheroid after 60-
min incubation with E -CA4 (25 μM). (c) The time course of E -CA4 fluorescence increase at the spheroid
periphery and central region, and (d) the corresponding measured average fluorescence intensities
(counts∕μm2) versus imaging depth. Images were obtained with a 20× air objective. Errors are
based on an average of those from the statistics of photon counting and the measured variation in inten-
sities of binned columns in the images.
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uptake into spheroids of MDA231 cells. Figure 3(c) shows that
intensity (Iedge) representing uptake of the E-CA4 from the
surrounding medium into the cells of the outer edge region
(thickness of 44 μm from the spheroid outer surface) follows
first-order kinetics [Eq. (1)] with a half-life of 3.5 min (k ¼
0.2 mm−1). The data for drug accumulation into the center
region (from the spheroid center to within 45 μm of the surface)
of the imaged slice of the spheroid show a sigmoidal shape that
is characteristic of the accumulation of a product in a series of
sequential reactions (i.e., A → B→ C where A might represent
drug in the suspending medium, B is the drug in the peripheral
cell layer, and C is the drug at the spheroid center). Accordingly,
the curve in Fig. 3(c) for increase in intensity of fluorescence in
the central region (Icenter) shows a good fit to the appropriate
kinetics32 for species C [Eq. (2)] with similar, though by necessity
nonidentical, first-order rate constants k1 ≅ k2 ≅ 0.15 min−1.
After drug uptake was completed, a series of images in the
Z-dimension were recorded using E-CA4 fluorescence and are
shown in Figs. 3(b1) to 3(b7). These show clearly resolved cel-
lular distribution at the base of the spheroid [Figs. 3(b2) at
25 μm], but reveal increasing lack of imaging capability toward
the spheroid equator in the same manner as was revealed in the
FITC-dextrin images in Fig. 2.
Iedge ¼ Imax½1 − expð−ktÞ; (1)
Icentre¼ Imax

1þ 1ðk1−k2Þ
½k2 expð−k1tÞ−k1 expð−k2tÞ

:
(2)
These two-photon excitation FLIM results obtained with a
standard confocal microscope system with a Nikon 20× (NA
0.75, WD, 1 mm) air objective show the ability to image detail
in spheroids at depths only up to about 100 μm, possibly due to
scattering of the violet wavelength (380–400 nm) of E-CA4
fluorescence. In addition to the kinetics of E-combretastatin
uptake into the spheroid discussed above, it is also evident from
the images in Fig. 3 [e.g., (b4) to (b6)] that the brightness of the
image at the spheroid perimeter is greater than in the central
regions. This reflects the lower optical attenuation of excitation
and fluorescence by the lower cell thickness at the spheroid
periphery compared with that closer to the spheroid center.
In our application of two-photon-induced isomerization of
combretastatins applied to tumor phototherapy, there is clearly
the need to obtain effective deeper tissue penetration. It is worth
noting that two-photon excitation phototherapy requires only
light delivery to the target, whereas multiphoton imaging
needs both delivery and collection of photons. Thus, the multi-
photon activation process in the red to NIR region is likely to be
effective at greater depths than that reported here.
The concentrations of E-CA4 in the spheroid shown in Fig. 3
have been calculated using FLIM data and an example is shown
in Fig. 4(a) using the image after 10 min incubation shown in
Fig. 3(a4). The FLIM image [Fig. 4(b)] and the fluorescence
lifetime distribution [Fig. 4(d)] show a fairly narrow distribution
of lifetimes peaking at 1014 ps, and a good fit to a single expo-
nential fluorescence decay is evident at an individual location
(averaged over 4 pixels) in the image [Fig. 4(c)]. The concen-
trations at each pixel in the image are calculated as previously
described for cell monolayers,23 using a series of E-CA4 solu-
tions in DMSO for intensity calibration and making an adjust-
ment for lifetime in the spheroid image, since for E-CA4, the
fluorescence quantum yield is directly proportional to lifetime.23
The concentration image [Fig. 4(a)] shows that intracellular
concentrations of E-CA4 reach values of 10–20 mM compared
with the 25 μM concentration of E-CA4 in the added medium.
The concentrations are also reflected in the relative color
Fig. 4 Concentration profiles for E -CA4 within a C8161 melanoma cell spheroid obtained by FLIM.
(a) Concentration map for E -CA4 in the spheroid after 10 min incubation based on the image in
Fig. 3(a4). (b) FLIM image of the imaged plane of the spheroid. (c) Fluorescence decay trace for
E -CA4 within the spheroid showing a good single exponential. (d) Fluorescence lifetime distribution
for the image shown in (b). The dimensions of the field (X, Y) in A and B are 350 μm2.
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brightnesses of the lifetime image [Fig. 4(b)]. This high extent of
accumulation of E-CA4 into cells was previously observed in
cell monolayers and attributed to the high lipophilicity of the
compound.23
3.2 Combretastatin Isomerization in Agarose Gels
The problem of obtaining a tightly focused laser beam at depth
within tissues depends on light scatter and absorption within the
medium. However, recently improved lens designs offer consid-
erable improvements and commercial developments have led to
new lenses that are specifically designed to meet the demands of
multiphoton microscopy. In order to compare effective penetra-
tion depths for our photochemical combretastatin isomerization,
we have studied agarose gels containing the nonfluorescent
Z-combretastatin isomer. While this is the reverse reaction of
that required for combretastatin activation with regard to tar-
geted cancer therapy, it allows visualization of the isomerization
reaction by formation of the readily detected fluorescence of the
resulting E-isomer.
An aqueous solution containing agarose (1%) and Z-CA4
(1 mM) produced a scattering gel, in which the combretastatin
appears to have precipitated. The gel was placed into an Ibidi
μ-Slide Angiogenesis on the inverted confocal fluorescence
microscope and could be irradiated from below with the pulsed
(200 fs) laser beam at 625 nm in order to attempt photoisome-
rization by two-photon absorption. The gel was irradiated by
focusing the laser at a selected focal plane and then raster scan-
ning over a central 83 × 112 μm2 area of the available field of
view. This process was repeated in the same gel sample at
increasing depths in the sample. A Z-stack image of the gel
in situ using the same laser wavelength at reduced power then
recorded fluorescence from any E-combretastatin resulting from
two-photon isomerization of the Z-combretastatin. Figure 5
shows the results obtained using the Nikon CF175 Apo
25×WMP (NA 1.10 WD 2.0) water dipping objective, specifi-
cally designed for multiphoton applications. The Z-scan image
[Fig. 5(a)] clearly reveals the irradiated planes imaged by fluo-
rescence of an irradiation product. It is notable that photoisome-
rization may be initiated and imaged at depths of up to 1700 μm
within the gel, although the efficiency of activation falls with
distance [Fig. 5(b)]. The particulate nature of the Z-CA4 precipi-
tate within the gel is revealed by the gray-scale image of
the irradiated area at a depth of 700 μm within the gel
[Fig. 5(c)]. The ability of this lens to perform at working dis-
tances approaching 2 mm shows that combretastatin activation
may be achievable within tissues. Comparable experiments
with the other available lenses, such as the Nikon 60× water
immersion objective (N.A. 1.2), which we have routinely
used in previous studies of cell monolayers23,24 demonstrate
photoisomerization is limited to much lower penetration depths
typically of around 200 μm for the 60× water immersion objec-
tive, and up to around 500 μm with the Nikon 20× air objective.
3.3 Comparison of Two- and Three-Photon
Absorptions by Combretastatins
The efficiency for combretastatin drug activation by E → Z pho-
toisomerization will depend on the effects of wavelength on
optical tissue penetration and the extent of light absorption,
the latter being determined by the absorption cross section.
Two-photon absorption cross sections for E-CA4F are highly
wavelength dependent and increase as the excitation wavelength
decreases from 630 to 560 nm.14 We have found that cyano-sub-
stituted combretastatins have greatly enhanced two-photon
absorption cross sections in this wavelength region presumably
due to the charge transfer nature of the electronic state by virtue
of the electron withdrawing cyano-group.33,34 One such com-
pound that is accumulated in cells in the same way as E-
CA4 is E-CA4CN, a B-ring 4-cyano substituted combretastatin
analog (Fig. 1).24 Further access to the tissue optical window at
>650 nm is made possible via possible three-photon absorption.
This was explored for E-CA4CN which has a one-photon
absorption maximum in DMSO at 344 nm thus offering the
Fig. 5 Images of an agarose gel [1% in phosphate buffered saline (PBS)] containing Z -CA4 (1 mM)
showing fluorescence in planes irradiated with a rastered focused laser beam at 625 nm. (a) 3-D pro-
jection of fluorescence intensity revealing irradiated planes within the gel. (b) Plot of integrated fluores-
cence intensity versus irradiation depth in the gel. (c) A 2-D image of the fluorescence at 700 μm into the
gel. Recorded using a Nikon 25×, 1.1 NA, 2 mmworking distancemultiphoton objective. Errors are based
on an average of those from the statistics of photon counting and the measured variation in intensities of
binned columns in the images.
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possibility of three-photon absorption in the region of 900–
1000 nm which is further into the tissue window than the region
of 625 nm explored for two-photon excitation as above, with the
results shown in Fig. 6. The power (P) dependence for fluores-
cence intensity (I) in processes involving n photons is expected
to follow Eq. (3), where K is the proportionality constant
I ¼ KPn: (3)
Log–log plots of fluorescence intensity versus laser power
have slopes of 2.05 0.08 and 2.75 0.08 at 820 and 930 nm,
respectively [Fig. 6(a)], indicating the two- and three-photon
processes, respectively. The three-photon process appears to
dominate at wavelengths>900 nm [Fig. 6(b)]. The much higher
cross section for two-photon absorption compared with that for
the three-photon process is probably the reason why a value of 3
is not reached at the longer wavelengths. The relative efficiency
of excitation at the two wavelengths was estimated from the
value of K in Eq. (3) irrespective of the value of n, and is plotted
versus wavelength in Fig. 6(b). This shows a surprisingly sharp
absorption peak in the three-photon cross section at 930 nm,
considering that the one-photon spectrum has a full width at
half maximum of ca. 60 nm, and indicates the need for careful
measurement of multiphoton spectra. Although the efficiency of
three-photon absorption is considerably less than for two
photons, imaging of E-CA4CN within cells is possible at mod-
erate laser powers as demonstrated by the FLIM data in Fig. 6(c)
using 1.8 mWof laser power at the sample at 930 nm. The inte-
grated intensity of the image versus laser power shows a value of
n ¼ 2.72 similar to that obtained in solution [Fig. 6(d)] at this
wavelength. The FLIM images show E-CA4CN to be concen-
trated within the cytoplasmic region with an intracellular peak
fluorescence lifetime of E-CA4CN of 0.80 ns (χ2 ¼ 1.35),
which was shorter than the lifetimes found for the other E-com-
bretastatins, but corresponds well to the fluorescence lifetime of
E-CA4CN measured in ethylene glycol solution (0.84 ns). The
shorter fluorescence lifetimes of E-CA4CN in nonpolar lipid
droplets are in accordance with the finding that fluorescence
lifetimes in the nonpolar solvents cyclohexane and hexane
were also short compared to the lifetimes of all other E-combre-
tastatin derivatives within nonpolar environments.34
4 Conclusions
Real-time imaging of E-combretastatin uptake in live mamma-
lian cell spheroids has been demonstrated by multiphoton-
excited fluorescence microscopy. Although only approximately
half of the spheroid may be effectively imaged because of pho-
ton scatter and absorption, particularly in the ultraviolet spectral
region where more scattering (∝ λ−4) is expected, the method is
able to probe sections close to the spheroid equator and
Fig. 6 Multiphoton excited fluorescence from E -CA4CN. (a) Log–log plots of fluorescence intensity ver-
sus laser power at 820 nm (square) and 930 nm (filled square) for E -CNCA4 (10 mM) in dimethyl sulf-
oxide. (b) Effect of wavelength on the power dependency [n, Eq. (3), left scale filled square] and
proportionality constant [K , Eq. (3), arbitrary units, right hand scale square]. (c) FLIM images of
E -CA4CN in HeLa cells obtained 60 min after addition of E -CA4CN (50 μM) to the medium and on exci-
tation at 930 nm (1.8 mW). (d) Plot of integrated intensity in FLIM image (c) versus excitation power at
930 nm.
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demonstrate rapid initial uptake at the spheroid periphery fol-
lowed by diffusion to the spheroid interior. Equilibration of
E-combretastatin throughout the spheroid is effectively com-
pleted within 30 min and this is faster than has been observed
for Cy-3 labeled aptamer or peptide in C6 cell spheroids.35 Our
approach has the advantage of tracking uptake by intrinsic fluo-
rescence without the need for a conjugated fluorescence probe
and permits imaging in live cell spheroids rather than using fixed
specimens. Although the difference in uptake into a spheroid
may be accounted for by the difference in molecular size, it
may be noted that doxorubicin penetration into spheroids is
also slow with a half-life of hours and penetration of derivatized
quantum dots showed a strong dependence on charge.29
Confocal microscopy has also been used to study small inhibi-
tory RNA uptake in multicellular spheroids and revealed pen-
etration only into the spheroid periphery.36 The inability to
image a complete spheroid by multiphoton and confocal micros-
copy has been previously noted 29,31 and light sheet microscopy
appears to provide superior imaging capability for spheroids.37
Various 3-D models for PDT have been investigated includ-
ing tumor spheroids, tumor nodules, and scaffold-based cul-
tures.12 Using spheroids, Foster et al.38 found evidence that
using the singlet oxygen generating photosensitizer photofrin
resulted in substantial oxygen depletion and the formation of
hypoxic regions in the spheroid center where oxygen diffusion
is limited and led to enhanced survival of cells in this region
after treatment. PDT involving oxygen-dependent sensitizer
mechanisms will, therefore, potentially limit the application
of PDT to solid tumors which likewise possess hypoxic regions.
However, one photosensitizer, EtNBS (5-ethylamino-9-diethyl-
aminobenzo[a]phenothiazinium chloride] has been found39–41 to
effectively penetrate into a 3-D tumor nodule model (diameter
200 μm) and spheroids, and kills hypoxic cells at the core
through an oxygen-independent Type I radical mechanism.39
Similarly, E-combretastatins are shown here to readily diffuse
to the central regions of similar diameter tumor spheroids
and since their photoisomerization and activation to the Z-iso-
mer is an oxygen independent process, they should be effective
within hypoxic regions of cell models and tumors. We have
attempted to study cell killing within small defined regions
of tumor spheroids following treatment using the same approach
as in our previous successful work25 with cell monolayers.
These experiments involved E-combretastatin uptake into the
spheroid, photoirradiation (typically of a 150 × 50 × 10 μm3
volume at 50 μm height into the spheroid), and incubation
for 24 to 48 h followed by apoptotic cell labeling. Although
we have observed a lawn of dead cells at the base of the spheroid
following irradiation, we were unable to identify a region of
dead or apoptotic cells corresponding to the irradiated region
within the spheroid. It may be that with the spheroid environ-
ment, dead cells are replaced within the 24–48 h incubation by
live cells from the regions that border the irradiated section on at
least three sides. Further studies are required with an alternative
more rapid assay to identify apoptosis in 3-D structures.
Although Z-combretastatins are primarily antivascular
agents, their ability to induce apoptosis suggests that oxygen
independent photoactivation of E-combretastatins should be
active against hypoxic cells within the center of spheroids
and tumor cores.37,38 This is seen as a potential major benefit
in external treatment of accessible tumors or in combination
with surgical resection for other sites such as the bile duct42
or skin. For example, PDT has been trialed for treating
melanoma, but outcomes show it to be generally resistant.
Problems include optical interference by melanin pigmentation,
melanin antioxidant properties, and apoptotic pathway defects.43
To overcome this, photosensitizers that absorb in the NIR spec-
tral region (700–800 nm) have been considered together with
interventions for reducing melanin pigmentation and immuno-
therapy approaches. Although localized E → Z activation and
toxicity of combretastatins could not be directly determined
in spheroids at this stage, it was possible to demonstrate two-
photon Z → E isomerization at depth within agarose gels.
This suggests that E-combretastatin activation within tissues
for tumor phototherapy is an achievable objective. Finally, it
has been shown that for suitable E-combretastatin molecules
with optimized cross sections, the two-photon imaging and acti-
vation may be extended to the three-photon regime within the
potential benefits of extending the activation wavelength further
into the NIR region. These findings make E-combretastatins
good candidates for targeted cancer therapy and our results dem-
onstrate the need for further studies into their potential use as
phototherapeutic agents. By affording localized delivery of
the active drug to the tumor site, the systemic toxicity that cur-
rently limits the clinical use of Z-combretastatins44 might be
avoided.
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